Medigene AG (MDG1.DE)
EUR 0.2
(15.32%)
EUR 0.2
(15.32%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 31.71 Million EUR | -38.63% |
| 2022 | 51.67 Million EUR | -13.1% |
| 2021 | 59.47 Million EUR | -20.44% |
| 2020 | 74.75 Million EUR | -31.56% |
| 2019 | 109.21 Million EUR | -15.72% |
| 2018 | 129.59 Million EUR | 15.77% |
| 2017 | 111.93 Million EUR | 0.2% |
| 2016 | 111.71 Million EUR | -1.6% |
| 2015 | 113.53 Million EUR | 59.27% |
| 2014 | 71.28 Million EUR | 35.38% |
| 2013 | 52.65 Million EUR | -14.04% |
| 2012 | 61.25 Million EUR | 14.94% |
| 2011 | 53.29 Million EUR | -8.43% |
| 2010 | 58.2 Million EUR | -11.45% |
| 2009 | 65.72 Million EUR | -18.61% |
| 2008 | 80.74 Million EUR | -29.74% |
| 2007 | 114.92 Million EUR | -7.42% |
| 2006 | 124.13 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 28.81 Million EUR | 0.0% |
| 2024 Q1 | - EUR | -100.0% |
| 2023 Q2 | 42.17 Million EUR | 0.0% |
| 2023 Q4 | 31.71 Million EUR | 0.0% |
| 2023 Q3 | 31.71 Million EUR | -24.8% |
| 2023 FY | 31.71 Million EUR | -38.63% |
| 2023 Q1 | - EUR | -100.0% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 Q4 | 51.67 Million EUR | 0.0% |
| 2022 Q2 | 76.49 Million EUR | 0.0% |
| 2022 FY | 51.67 Million EUR | -13.1% |
| 2022 Q3 | 51.67 Million EUR | -32.45% |
| 2021 Q4 | 59.47 Million EUR | 0.0% |
| 2021 Q3 | 59.47 Million EUR | -11.07% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 Q2 | 66.87 Million EUR | 0.0% |
| 2021 FY | 59.47 Million EUR | -20.44% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q4 | 74.75 Million EUR | 0.0% |
| 2020 Q2 | 93.1 Million EUR | 0.0% |
| 2020 FY | 74.75 Million EUR | -31.56% |
| 2020 Q3 | 74.75 Million EUR | -19.71% |
| 2019 Q2 | 121.6 Million EUR | -5.16% |
| 2019 FY | 109.21 Million EUR | -15.72% |
| 2019 Q4 | 109.21 Million EUR | -6.96% |
| 2019 Q3 | 117.38 Million EUR | -3.47% |
| 2019 Q1 | 128.21 Million EUR | -1.06% |
| 2018 FY | 129.59 Million EUR | 15.77% |
| 2018 Q4 | 129.59 Million EUR | -3.28% |
| 2018 Q1 | 107.86 Million EUR | -3.64% |
| 2018 Q2 | 138.63 Million EUR | 28.53% |
| 2018 Q3 | 133.99 Million EUR | -3.35% |
| 2017 Q3 | 114.87 Million EUR | -4.13% |
| 2017 Q1 | 105.83 Million EUR | -5.26% |
| 2017 FY | 111.93 Million EUR | 0.2% |
| 2017 Q4 | 111.93 Million EUR | -2.56% |
| 2017 Q2 | 119.82 Million EUR | 13.21% |
| 2016 Q4 | 111.71 Million EUR | -3.0% |
| 2016 FY | 111.71 Million EUR | -1.6% |
| 2016 Q3 | 115.17 Million EUR | 9.07% |
| 2016 Q2 | 105.59 Million EUR | -4.08% |
| 2016 Q1 | 110.09 Million EUR | -3.03% |
| 2015 Q1 | 69.72 Million EUR | -2.18% |
| 2015 Q2 | 74.65 Million EUR | 7.07% |
| 2015 FY | 113.53 Million EUR | 59.27% |
| 2015 Q4 | 113.53 Million EUR | -1.9% |
| 2015 Q3 | 115.73 Million EUR | 55.02% |
| 2014 Q4 | 71.28 Million EUR | 3.01% |
| 2014 Q2 | 57.17 Million EUR | -2.68% |
| 2014 FY | 71.28 Million EUR | 35.38% |
| 2014 Q1 | 58.74 Million EUR | 11.57% |
| 2014 Q3 | 69.2 Million EUR | 21.04% |
| 2013 Q1 | 58.26 Million EUR | -4.88% |
| 2013 FY | 52.65 Million EUR | -14.04% |
| 2013 Q3 | 54.07 Million EUR | -5.38% |
| 2013 Q2 | 57.15 Million EUR | -1.91% |
| 2013 Q4 | 52.65 Million EUR | -2.63% |
| 2012 Q3 | 62.27 Million EUR | -3.65% |
| 2012 Q1 | 49.54 Million EUR | -7.03% |
| 2012 FY | 61.25 Million EUR | 14.94% |
| 2012 Q4 | 61.25 Million EUR | -1.64% |
| 2012 Q2 | 64.63 Million EUR | 30.46% |
| 2011 FY | 53.29 Million EUR | -8.43% |
| 2011 Q1 | 66.38 Million EUR | 14.07% |
| 2011 Q2 | 60.4 Million EUR | -9.01% |
| 2011 Q3 | 60.39 Million EUR | -0.02% |
| 2011 Q4 | 53.29 Million EUR | -11.76% |
| 2010 FY | 58.2 Million EUR | -11.45% |
| 2010 Q4 | 58.2 Million EUR | -13.01% |
| 2010 Q3 | 66.9 Million EUR | 1.11% |
| 2010 Q2 | 66.16 Million EUR | 5.16% |
| 2010 Q1 | 62.92 Million EUR | -4.26% |
| 2009 FY | 65.72 Million EUR | -18.61% |
| 2009 Q4 | 65.72 Million EUR | 0.0% |
| 2008 FY | 80.74 Million EUR | -29.74% |
| 2007 FY | 114.92 Million EUR | -7.42% |
| 2006 FY | 124.13 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| BioNTech SE | 23 Billion EUR | 99.862% |
| CureVac N.V. | 788.89 Million EUR | 95.98% |
| Biotest Aktiengesellschaft | 1.44 Billion EUR | 97.804% |
| Biotest Aktiengesellschaft | 1.44 Billion EUR | 97.804% |
| BRAIN Biotech AG | 70.93 Million EUR | 55.29% |
| Formycon AG | 890.36 Million EUR | 96.438% |
| Heidelberg Pharma AG | 70.35 Million EUR | 54.919% |